

Table S1

Spearman's rank correlation coefficients for the correlation of plasma/blood levels the persistent contaminants between each other.

	PFOA	PFOS	PFHxS	PFNA	I-TEq	PCBs	β -HCH	pp-DDE	Hg	Cd
PFOS	0.67									
PFHxS	0.51	0.42								
PFNA	0.72	0.86	0.46							
I-TEq	0.67	0.46	0.24	0.54						
PCBs	0.72	0.49	0.43	0.61	0.78					
β-HCH	0.61	0.46	0.24	0.54	0.80	0.78				
pp-DDE	0.57	0.41	0.06	0.47	0.79	0.64	0.77			
Hg	0.08	0.00	-0.01	0.08	0.11	0.14	0.10	0.12		
Cd	0.02	-0.10	0.12	-0.04	-0.01	0.09	-0.03	-0.03	0.17	
Pb	0.23	0.05	0.09	0.12	0.26	0.20	0.23	0.20	0.00	0.08

Table S2 No observed adverse effect concentration (NOAEC) for PFOA derived as mean of the highest-dose quantile (yellow) below the first one showing a significant difference to the lowest-dose quantile.

anti-Hib			anti-Tetanus (IgG1)			anti-Diphtheria		
Quintiles			Deciles			Quintiles		
group			group			group		
mean	N	SD	mean	N	SD	mean	N	SD
Q1	3.4	20	1.84	0.68	0.98	Q1	3.4	20
Q2	8.5	20	1.84	0.71	0.98	Q2	8.5	20
Q3	14.8	20	1.84	0.84	0.98	Q3	14.5	20
Q4	19.4	20	1.50	0.55	0.09	Q4	18.9	20
Q5	25.7	18	1.19	0.60	0.003	Q5	25.3	20
Anova p 0.001			Anova p 0.002			Anova p 0.004		
p value			p value			p value		
Q1	3.4	20	1.07	0.31	0.77	Q1	3.4	20
Q2	8.5	20	1.04	0.44	0.77	Q2	8.5	20
Q3	14.5	20	1.02	0.39	0.67	Q3	14.5	20
Q4	18.9	20	1.02	0.35	0.61	Q4	18.9	20
Q5	25.3	20	0.74	0.36	0.003	Q5	25.3	20
Anova p 0.01			Anova p 0.013			Anova p 0.006		
p value			p value			p value		
Q1	2.8	10	1.14	0.39	0.34	Q1	2.8	10
Q2	4.0	10	1.00	0.20	0.34	Q2	4.0	10
Q3	6.6	10	0.89	0.49	0.22	Q3	6.6	10
Q4	10.4	10	1.19	0.35	0.79	Q4	10.4	10
Q5	13.6	10	0.87	0.37	0.13	Q5	13.6	10
Q6	15.5	10	1.18	0.36	0.83	Q6	15.5	10
Q7	17.8	10	1.13	0.21	0.93	Q7	17.8	10
Q8	20.0	10	0.91	0.42	0.22	Q8	20.0	10
Q9	22.4	10	0.81	0.35	0.07	Q9	22.4	10
Q10	28.1	10	0.66	0.37	0.01	Q10	28.1	10
Anova p 0.001			Anova p 0.002			Anova p 0.006		
p value			p value			p value		
Q1	2.8	10	1.78	0.58	0.70	Q1	2.8	10
Q2	4.0	10	1.90	0.79	0.70	Q2	4.0	10
Q3	6.6	10	1.97	0.78	0.56	Q3	6.6	10
Q4	10.4	10	1.71	0.64	0.80	Q4	10.4	10
Q5	13.7	10	1.77	0.78	0.96	Q5	13.6	10
Q6	15.9	10	1.91	0.92	0.72	Q6	15.5	10
Q7	18.3	10	1.68	0.66	0.73	Q7	17.8	10
Q8	20.5	10	1.33	0.38	0.06	Q8	20.0	10
Q9	23.0	10	1.10	0.70	0.03	Q9	22.4	10
Q10	29.1	8	1.30	0.46	0.07	Q10	28.1	10

Table S3

Correlation of the levels of PFOA and PFOS with anamnestic items regarding infections in the first year of life as well as CRP, adjusted for the number of siblings and the equivalent duration of breastfeeding (Spearman partial correlation coefficients; please note that the cohort size of $n=101$ implies that a $p=0.05$ roughly corresponds to $r=0.2$).

	PFOA	PFOS
Month of first infection	-0.18	0.01
Total number of infections	0.01	0.13
Number infections with fever	-0.10	0.09
Number antibiotic treatments	-0.08	0.06
Antibiotic ever	-0.09	0.02
Number Otitis media	0.01	0.10
Otitis media ever	0.01	0.08
3-day-fever already	-0.05	-0.04
Number pneumonia	-0.08	-0.01
Pneumonia ever	-0.08	-0.01
Number diarrhoea	0.02	-0.17
Diarrhoea ever	0.02	-0.18
Varicella already	-0.02	-0.16
Napkin candidiasis ever	0.06	0.10
Oral candidiasis ever	0.09	0.09
CRP	0.02	0.08

Figure S1

Boxplots of adjusted antibody levels in relation to levels of PFOA (this page) and PFOS (next page) as quintiles and deciles for Hib, tetanus (IgG1) and diphtheria.




Figure S1 (continued)









Figure S2 Empirical cumulative distribution functions of all PFOA quintiles together with the respective fitted normal distribution curves

